Current progress in immunotherapy of hepatocellular carcinoma

Affiliations

¹ Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Germany.
² Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Germany. Electronic address: galle@uni-mainz.de.

Editorial

Martin F Sprinzl et al. J Hepatol. 2017 Mar.

. 2017 Mar;66(3):482-484.

doi: 10.1016/j.jhep.2016.12.009. Epub 2016 Dec 21.

¹ Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Germany.
² Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Germany. Electronic address: galle@uni-mainz.de.

No abstract available

Keywords: Checkpoint inhibitors; Immunotherapy; Liver cancer; Therapy.

Comment on

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Duffy AG, et al. J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2. J Hepatol. 2017. PMID: 27816492 Free PMC article. Clinical Trial.